ArticleScientific reports2022
Identification of potential microRNA diagnostic panels and uncovering regulatory mechanisms in breast cancer pathogenesis.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- MicroRNA Expression Links Transportation Environmental Burden to Late-Stage Triple-Negative Breast Cancer.Genes · 2026Article
- Evaluation of serum microRNA-9-5p expression and its predicted target genes as potential biomarkers for breast cancer.Breast cancer (Tokyo, Japan) · 2026Article
- Article
- The assessment of breast cancer biomarkers in diagnosis, prognosis and treatment monitoring: integrated analysis.Journal of cancer research and clinical oncology · 2025Review
- Detection of Human Circulating and Extracellular Vesicle-Derived miRNAs in Serum of Humanized Mice Transplanted with Human Breast Cancer (HER2International journal of molecular sciences · 2025Article
- Deciphering the roles of non-coding RNAs in liposarcoma development: Challenges and opportunities for translational therapeutic advances.Non-coding RNA research · 2025Review
- Identification of an Exosomal miRNA Signature in Newly Diagnosed Essential Hypertensive Adults.British journal of biomedical science · 2025Article
- miR-200 family as new potential prognostic factor of overall survival of patients with WHO G2 and WHO G3 brain gliomas.Scientific reports · 2024Article
- miR-23b-3p, miR-126-3p and GAS5 delivered by extracellular vesicles inhibit breast cancer xenografts in zebrafish.Cell communication and signaling : CCS · 2024Article
- Targeting MicroRNAs with Small Molecules.Non-coding RNA · 2024Review
- miR-125 in Breast Cancer Etiopathogenesis: An Emerging Role as a Biomarker in Differential Diagnosis, Regenerative Medicine, and the Challenges of Personalized Medicine.Non-coding RNA · 2024Review
- MicroRNA as a promising molecular biomarker in the diagnosis of breast cancer.Frontiers in molecular biosciences · 2024Article
- Characterization of a miRNA Signature with Enhanced Diagnostic and Prognostic Power for Patients with Bladder Carcinoma.International journal of molecular sciences · 2023Article
- Review
- The Role of MicroRNAs in Breast Cancer and the Challenges of Their Clinical Application.Diagnostics (Basel, Switzerland) · 2023Review
- Dynamic Role of Exosome microRNAs in Cancer Cell Signaling and Their Emerging Role as Noninvasive Biomarkers.Biology · 2023Review
- MiRNAs in Hematopoiesis and Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2023Review
- MicroRNAs: Emerging as Highly Promising Biomarkers for Early Breast Cancer Screening.Journal of clinical and laboratory medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early diagnosis of breast cancer (BC), as the most common cancer among women, increases the survival rate and effectiveness of treatment. MicroRNAs (miRNAs) control various cell behaviors, and their dysregulation is widely involved in pathophysiological processes such as BC development and progress. In this study, we aimed to identify potential miRNA biomarkers for early diagnosis of BC. We also proposed a consensus-based strategy to analyze the miRNA expression data to gain a deeper insight into the regulatory roles of miRNAs in BC initiation. Two microarray datasets (GSE106817 and GSE113486) were analyzed to explore the differentially expressed miRNAs (DEMs) in serum of BC patients and healthy controls. Utilizing multiple bioinformatics tools, six serum-based miRNA biomarkers (miR-92a-3p, miR-23b-3p, miR-191-5p, miR-141-3p, miR-590-5p and miR-190a-5p) were identified for BC diagnosis. We applied our consensus and integration approach to construct a comprehensive BC-specific miRNA-TF co-regulatory network. Using different combination of these miRNA biomarkers, two novel diagnostic models, consisting of miR-92a-3p, miR-23b-3p, miR-191-5p (model 1) and miR-92a-3p, miR-23b-3p, miR-141-3p, and miR-590-5p (model 2), were obtained from bioinformatics analysis. Validation analysis was carried out for the considered models on two microarray datasets (GSE73002 and GSE41922). The model based on similar network topology features, comprising miR-92a-3p, miR-23b-3p and miR-191-5p was the most promising model in the diagnosis of BC patients from healthy controls with 0.89 sensitivity, 0.96 specificity and area under the curve (AUC) of 0.98. These findings elucidate the regulatory mechanisms underlying BC and represent novel biomarkers for early BC diagnosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.